CD8A and neoplasm: Emerging evidence has shown that RT can kill tumor cells directly by inducing double-stranded DNA breaks in tumor cells and induce immunogenic cell death to recruit antigen-specific CD8+ T cells and enhance the antitumor immune response by releasing immunogenic tumor-associated antigens and chemokines.32 33 In our preclinical mouse model, we chose an 8 Gy ×3 regimen for RT because this regimen has been shown to have better immunogenicity than single 20 Gy and 6 Gy ×5 regimens.31 34 However, the best fractionation approach for RT is still an area of debate that warrants further investigation.